VP of Fin., Information Technology, and CFO Vice President and General Manager - In Vitro Diagnostics Vice President - Research, Development, and Medical DevicesĬhief Operating Officer and Medical DevicesĬhief Financial Officer and Vice President - Finance Senior Vice President of Commercial, Business Development, and Medical Devices Senior Vice President and Chief Marketing Officer To read this article on click here.President, Chief Executive Officer, and Director
YAHOO FINANCE SRDX FREE
(SRDX) : Free Stock Analysis ReportĪbbott Laboratories (ABT) : Free Stock Analysis Report Click to get this free reportĪngioDynamics, Inc.
YAHOO FINANCE SRDX DOWNLOAD
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. These 7 were selected because of their superior potential for immediate breakout. Just Released: Zacks’ 7 Best Stocks for TodayĮxperts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.9% per year. Additionally, revenues of $72.8 million beat the consensus mark by 8%. The Zacks Consensus Estimate was of a loss per share of a couple ofcents. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.ĪngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.Ībbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. While Hologic sports a Zacks Rank #1 (Strong Buy), the other two presently carry a Zacks Rank#2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here. HOLX, Abbott Laboratories ABT and AngioDynamics, Inc. Some better-ranked stocks in the broader medical space that already announced quarterly results are Hologic, Inc. Surmodics currently carries a Zacks Rank #3 (Hold). Contraction of gross margin is also worrisome. However, the company registered a revenue decline in its Medical Device core unit. Besides, the FDA nod for Pounce Thrombus Retrieval System continues to instill confidence in the stock. The CE Mark for its SurVeil DCB and the FDA clearance for Sublime radial-access 0.014” PTA balloon catheter continued to raise optimism on the stock. Management remains upbeat about Surmodics’ partnership with Cook Medical for the commercialization of.
YAHOO FINANCE SRDX TRIAL
It also completed enrollment in the SWING first-in-human clinical trial for Sundance sirolimus-coated, below-the-knee drug coated balloon (DCB). It attained a $15-million TRANSCEND clinical report milestone under the SurVeil Development and Distribution Agreement with Abbott Vascular. The company saw an increase in Product sales and Research and development revenues in the quarter under review.
Surmodics exited the first quarter of fiscal 2021 on a mixed note.
Fiscal 2021 Guidanceĭue to the continued uncertainty surrounding the duration COVID-19 pandemic, Surmodics will not issue any financial guidance for the current fiscal year for the time being. Net cash used in operating activities came in at $4.3 million compared with $0.9 million in the year-ago period. The company exited the first quarter of fiscal 2021 with cash and cash equivalents of $35.8 million compared with $30.8 million in the fourth quarter of fiscal 2020. price-consensus-eps-surprise-chart | Surmodics, Inc.
0 kommentar(er)
